Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores.
about
Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophreniaA pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance lossPredicting EQ-5D-US and SF-6D societal health state values from the Osteoporosis Assessment Questionnaire.Predicting SF-6D utility scores from the neck disability index and numeric rating scales for neck and arm painMeasuring preferences for cost-utility analysis: how choice of method may influence decision-makingComparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights.Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia.The impact of comparative effectiveness research on health and health care spending.An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illnessCost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses.Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.Predicting SF-6D utility scores from the Oswestry disability index and numeric rating scales for back and leg pain.Is the value of a life or life-year saved context specific? Further evidence from a discrete choice experiment.Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC.Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment ProgramCost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United StatesCost-effectiveness of asenapine in the treatment of bipolar disorder in CanadaConverting condition-specific measures into preference-based outcomes for use in economic evaluation.Ordering errors, objections and invariance in utility survey responses: a framework for understanding who, why and what to do.Evaluation of content on EQ-5D as compared to disease-specific utility measures.The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy.Cost-Effectiveness of School-Based Prevention of Cannabis Use.Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone.A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populationsCost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.Village doctor-assisted case management of rural patients with schizophrenia: protocol for a cluster randomized control trial.Healthcare resource use in schizophrenia, EuroSC findings.Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials.Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates.Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
P2860
Q24815361-01B8F04D-1F34-47C5-8515-3FDC49D1E3A9Q33410397-1FC2CA2F-81E7-4AC4-A83A-20EAB03D1A54Q33597217-5694DBF4-ADF1-40B9-8BEA-264178E09C0FQ34419838-4A5AC3C1-CEC8-4EA1-A4BC-E79FF2099483Q34614168-2C2477FC-5B11-4717-B472-9036F0EEE77CQ34748545-77B19E61-D741-448A-B1B7-2BB933DD01A3Q35101645-A0F35E2F-F139-4E0D-BBC7-C7E8B33EB689Q35622994-93480DC6-106C-4427-B307-60116B3EAB17Q35875513-FECC228F-D9B3-470D-B2D2-B67ABD88009FQ36110777-547F4D4A-33DA-437D-9E67-22F7779D8F0FQ36198389-B1D250FA-8524-40A3-BE0E-8B28CB014C0EQ36418191-D5BF04A3-63A6-4625-8CFA-EA33392B2EB1Q36693581-93E6192E-EED9-4BDC-82E1-DEF5DFF13B0DQ36795862-10F61AA2-4FF1-4E2B-A07C-FF23CE67611CQ36990173-C8333B30-42BC-4E8A-B0A0-56E71E072848Q36994849-1A79126C-D634-4CD7-BEEB-F4CB5566A2B3Q37185914-DEF1F159-70B5-4DEF-B0C7-28098BA8E258Q37528010-8E4C46F3-ACAA-4686-9225-94ADBED43D7AQ37763123-15134046-132F-4AA2-9C79-1FCC0EB3E08AQ37891049-32C31A08-096F-46AF-8652-294A41669426Q38021389-5371C3FE-AAB9-423B-A39F-D636BF1B4863Q38167693-A11A298B-53A8-4F2E-A50E-0B56495E1563Q38212030-FED0A815-2CAA-4331-9039-8605BB23B40BQ38364288-B1057D79-407B-416B-AA66-3A5C111220E3Q38478523-B5984595-0DF8-41C1-84DE-34A04EB7843EQ38782286-44BDBE70-8A67-4C29-818E-0C50DCCD28CFQ38859087-44FD3FA2-48F1-46AF-8F40-C503CF4A400BQ39625587-03207412-710F-4F3C-9BDF-709CACD5DE2BQ41656775-991B98CC-FBA0-4242-901A-BF7FCA15BA2AQ41965991-1105160C-8498-4221-BEB8-6F84F50E5303Q42582836-A21726EC-3401-457B-8D1D-9D1C94FD2559Q42687642-71597DED-55AD-4367-8B7E-6433C3A41E17Q43280734-153C5AB3-8B35-4EE3-AF83-79D78F8D3166Q46837812-10C40FFF-DD95-41AD-9C91-BB98CF08616EQ47225222-DEF0BBCC-5EBB-4BBB-9BED-08F5890A23BEQ52800015-47027E00-D443-4488-A293-B8B655CB14CEQ56790547-3F7480E2-EC4C-4808-BC5D-ED4F4C69C700
P2860
Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Public preferences for health ...... negative symptom scale scores.
@en
Public preferences for health ...... negative symptom scale scores.
@nl
type
label
Public preferences for health ...... negative symptom scale scores.
@en
Public preferences for health ...... negative symptom scale scores.
@nl
prefLabel
Public preferences for health ...... negative symptom scale scores.
@en
Public preferences for health ...... negative symptom scale scores.
@nl
P2093
P1476
Public preferences for health ...... negative symptom scale scores.
@en
P2093
Ann P Sturley
Leslie A Lenert
Marcia Rupnow
Mark H Rapaport
Penny E Mohr
Shannon Chavez
P304
P356
10.1016/J.SCHRES.2003.10.010
P407
P577
2004-11-01T00:00:00Z